<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>364</serviceExecutionTime><Drug id="69057"><DrugName>anti-miR-33 antisense oligonucleotide (cardiovascular disease/ metabolic disease), Regulus/ New York University/ AstraZeneca</DrugName><DrugSynonyms><Name><Value>anti-miR-33 antisense oligonucleotide (cardiovascular disease/ metabolic disease), Regulus/ New York University</Value></Name><Name><Value>anti-miR-33 antisense oligonucleotide (cardiovascular disease/ metabolic disease), Regulus/ New York University/ AstraZeneca</Value></Name></DrugSynonyms><CompanyOriginator id="1034580">Regulus Therapeutics Inc</CompanyOriginator><CompaniesSecondary><Company id="1034580">Regulus Therapeutics Inc</Company><Company id="14190">AstraZeneca plc</Company><Company id="20646">New York University</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1034580" type="Company"><TargetEntity id="5000117079" type="organizationId">Regulus Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="20646" type="Company"><TargetEntity id="4295979103" type="organizationId">New York University</TargetEntity></SourceEntity><SourceEntity id="33" type="ciIndication"><TargetEntity id="I70" type="ICD10"></TargetEntity><TargetEntity id="440" type="ICD9"></TargetEntity><TargetEntity id="D050197" type="MeSH"></TargetEntity><TargetEntity id="-848966698" type="omicsDisease"></TargetEntity><TargetEntity id="208" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"></TargetEntity><TargetEntity id="D002318" type="MeSH"></TargetEntity><TargetEntity id="-1500764314" type="omicsDisease"></TargetEntity><TargetEntity id="182" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="655" type="ciIndication"><TargetEntity id="10058097" type="MEDDRA"></TargetEntity><TargetEntity id="D008659" type="MeSH"></TargetEntity><TargetEntity id="-652126003" type="omicsDisease"></TargetEntity><TargetEntity id="961" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="38419" type="Action"><TargetEntity id="3776" type="Mechanism">MicroRNA Modulators</TargetEntity><TargetEntity id="5315" type="Mechanism">MIR122 Inhibitors</TargetEntity><TargetEntity id="5488" type="Mechanism">MIR489 Inhibitors</TargetEntity><TargetEntity id="5111" type="Mechanism">MIR155 Inhibitors</TargetEntity><TargetEntity id="5442" type="Mechanism">MIR33B Inhibitors</TargetEntity><TargetEntity id="5441" type="Mechanism">MIR33A Inhibitors</TargetEntity><TargetEntity id="4639" type="Mechanism">MIR15B Inhibitors</TargetEntity><TargetEntity id="4637" type="Mechanism">MIR92A Inhibitors</TargetEntity><TargetEntity id="4992" type="Mechanism">MIR181a Inhibitors</TargetEntity><TargetEntity id="5051" type="Mechanism">MIR197 Inhibitors</TargetEntity><TargetEntity id="5645" type="Mechanism">MIR181b Inhibitors</TargetEntity><TargetEntity id="5533" type="Mechanism">MIR144 Inhibitors</TargetEntity><TargetEntity id="5599" type="Mechanism">MIR107 Inhibitors</TargetEntity><TargetEntity id="5532" type="Mechanism">MIR134 Inhibitors</TargetEntity><TargetEntity id="5525" type="Mechanism">MIR146a Inhibitors</TargetEntity><TargetEntity id="5465" type="Mechanism">MIR103-1 Inhibitors</TargetEntity><TargetEntity id="5529" type="Mechanism">MIR451 Inhibitors</TargetEntity><TargetEntity id="4372" type="Mechanism">MIR221 Inhibitors</TargetEntity><TargetEntity id="5646" type="Mechanism">MIR130 Inhibitors</TargetEntity><TargetEntity id="5528" type="Mechanism">MIR27B Inhibitors</TargetEntity><TargetEntity id="5459" type="Mechanism">MIR424 Inhibitors</TargetEntity><TargetEntity id="4878" type="Mechanism">MicroRNA-328-3p Inhibitors</TargetEntity><TargetEntity id="5161" type="Mechanism">MIR652 Inhibitors</TargetEntity><TargetEntity id="5531" type="Mechanism">MIR208a Inhibitors</TargetEntity><TargetEntity id="3248" type="Mechanism">MIR122a Inhibitors</TargetEntity><TargetEntity id="5108" type="Mechanism">MIR222 Inhibitors</TargetEntity><TargetEntity id="4987" type="Mechanism">MIR22 Inhibitors</TargetEntity><TargetEntity id="4976" type="Mechanism">MIR29 Inhibitors</TargetEntity><TargetEntity id="4630" type="Mechanism">MIR96 Inhibitors</TargetEntity><TargetEntity id="3802" type="Mechanism">MIR21 Inhibitors</TargetEntity><TargetEntity id="5271" type="Mechanism">MIR31 Inhibitors</TargetEntity><TargetEntity id="4641" type="Mechanism">MIR195 Inhibitors</TargetEntity><TargetEntity id="4640" type="Mechanism">MIR16-1 Inhibitors</TargetEntity><TargetEntity id="4616" type="Mechanism">MIR24 Inhibitors</TargetEntity><TargetEntity id="3777" type="Mechanism">MIR122 Inhibitors</TargetEntity><TargetEntity id="3851" type="Mechanism">MIR10B Inhibitors</TargetEntity><TargetEntity id="5554" type="Mechanism">MIR124 Inhibitors</TargetEntity><TargetEntity id="5534" type="Mechanism">MIR320a Inhibitors</TargetEntity><TargetEntity id="4638" type="Mechanism">MIR15A Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="33">Atherosclerosis</Indication><Indication id="57">Cardiovascular disease</Indication><Indication id="655">Metabolic disorder</Indication></IndicationsSecondary><ActionsSecondary><Action id="38419">miRNA agent</Action><Action id="59620">Unspecified drug target</Action><Action id="7294">Antisense oligonucleotide inhibitor</Action><Action id="965">Cardiovascular agent</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="603">Systemic formulation unspecified</Technology><Technology id="569">Oligonucleotide antisense</Technology></Technologies><EphmraCodes><Ephmra><Code>C</Code><Name>CARDIOVASCULAR SYSTEM</Name></Ephmra></EphmraCodes><LastModificationDate>2017-12-09T20:14:43.000Z</LastModificationDate><ChangeDateLast>2016-12-20T00:00:00.000Z</ChangeDateLast><AddedDate>2010-11-17T11:46:18.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1034580" linkType="Company"&gt;Regulus therapeutics&lt;/ulink&gt;, a joint venture between &lt;ulink linkID="17269" linkType="Company"&gt;Isis Pharmaceuticals&lt;/ulink&gt; and &lt;ulink linkID="29927" linkType="Company"&gt;Alnylam Pharmaceuticals&lt;/ulink&gt;,  in collaboration with &lt;ulink linkID="20646" linkType="Company"&gt;New York University&lt;/ulink&gt; and &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt;, was investigating the use of anti-miR-33 antisense oligonucleotides, including those targeting  miR-33a and miR-33b, for the potential treatment of cardiovascular and metabolic diseases (including atherosclerosis and metabolic syndrome) [&lt;ulink linkID="1145355" linkType="Reference"&gt;1145355&lt;/ulink&gt;], [&lt;ulink linkID="1148579" linkType="Reference"&gt;1148579&lt;/ulink&gt;], [&lt;ulink linkID="1180217" linkType="Reference"&gt;1180217&lt;/ulink&gt;], [&lt;ulink linkID="1315575" linkType="Reference"&gt;1315575&lt;/ulink&gt;]. By November 2010, preclinical studies were underway [&lt;ulink linkID="1145355" linkType="Reference"&gt;1145355&lt;/ulink&gt;], [&lt;ulink linkID="1148579" linkType="Reference"&gt;1148579&lt;/ulink&gt;]; in July 2013, preclinical development was ongoing [&lt;ulink linkID="1454596" linkType="Reference"&gt;1454596&lt;/ulink&gt;]. In February 2014, the companies terminated the miR-33 program as a collaboration target [&lt;ulink linkID="1529722" linkType="Reference"&gt;1529722&lt;/ulink&gt;]. In November 2016, preclinical data were presented [&lt;ulink linkID="1872041" linkType="Reference"&gt;1872041&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2016, preclinical data were presented at the AHA's Scientific Sessions 2016 in New Orleans, LA. In vivo, inhibition of miR-33 promoted autophagy in macrophage foam cells. Anti-miR-33-induced lipid droplet catabolism was autophagy-dependent. In Ld1r-/- mice, anti-miR-33 treatment restored defective autophagy [&lt;ulink linkID="1872041" linkType="Reference"&gt;1872041&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2013, preclinical data had demonstrated a 35% reduction in the arterial plaque size in a mouse model of atherosclerosis [&lt;ulink linkID="1454596" linkType="Reference"&gt;1454596&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, preclinical data were presented at AHA's Arteriosclerosis, Thrombosis and Vascular Biology  2011 Scientific Sessions  in Chicago, IL. Results showed non-human primates treated with anti-miR-33 antisense oligonucleotides for 12 weeks had a 50% increase in HDL cholesterol and a 50% decrease in blood triglycerides compared with control. The expression of miR-33a and miR-33b target genes was also increased [&lt;ulink linkID="1187822" linkType="Reference"&gt;1187822&lt;/ulink&gt;]. Data showing similar effects in mice were published in June 2011 [&lt;ulink linkID="1197894" linkType="Reference"&gt;1197894&lt;/ulink&gt;], [&lt;ulink linkID="1198139" linkType="Reference"&gt;1198139&lt;/ulink&gt;]. In September 2011, similar data were presented at the 7th Annual Meeting of the Oligonucleotide Therapeutics Society in Copenhagen, Denmark [&lt;ulink linkID="1221104" linkType="Reference"&gt;1221104&lt;/ulink&gt;]. In October 2011, similar data were published [&lt;ulink linkID="1232126" linkType="Reference"&gt;1232126&lt;/ulink&gt;], [&lt;ulink linkID="1232365" linkType="Reference"&gt;1232365&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2010, preclinical data were presented at the AHA Scientific Sessions in Chicago, IL. In LDLr-/- mice  with established atherosclerosis, treatment with anti-miR-33  increased HDL and reverse cholesterol transport, and promoted regression of atherosclerotic lesion [&lt;ulink linkID="1145355" linkType="Reference"&gt;1145355&lt;/ulink&gt;], [&lt;ulink linkID="1148579" linkType="Reference"&gt;1148579&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1034580">Regulus Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-27T00:00:00.000Z</StatusDate><Source id="1529722" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1034580">Regulus Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="33">Atherosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-27T00:00:00.000Z</StatusDate><Source id="1529722" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20646">New York University</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="655">Metabolic disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-27T00:00:00.000Z</StatusDate><Source id="1529722" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="33">Atherosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-27T00:00:00.000Z</StatusDate><Source id="1529722" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20646">New York University</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-27T00:00:00.000Z</StatusDate><Source id="1529722" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1034580">Regulus Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="655">Metabolic disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-27T00:00:00.000Z</StatusDate><Source id="1529722" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1034580">Regulus Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-11-16T00:00:00.000Z</StatusDate><Source id="1145355" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20646">New York University</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="655">Metabolic disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-03-30T00:00:00.000Z</StatusDate><Source id="1180217" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="33">Atherosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-08-14T00:00:00.000Z</StatusDate><Source id="1315575" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20646">New York University</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-11-16T00:00:00.000Z</StatusDate><Source id="1145355" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1034580">Regulus Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="33">Atherosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-08-14T00:00:00.000Z</StatusDate><Source id="1315575" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1034580">Regulus Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="655">Metabolic disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-03-30T00:00:00.000Z</StatusDate><Source id="1180217" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17269">Ionis Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20646">New York University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="134337" title="Regulus and the New York University to collaborate on the research of anti-miR-33 antisense oligonucleotide  "></Deal><Deal id="141063" title="Regulus and AstraZeneca to develop microRNA therapies for cardiovascular, metabolic and oncology diseases      "></Deal></Deals><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>